# Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

> **NCT02482272** · PHASE4 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 90 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Lamivudine
- **DRUG:** Adefovir
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT02482272
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2017-01
- **Final completion:** 2017-05
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2015-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482272, "Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02482272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*